TGA / PMDA / NMPA · Asia-Pacific
inhibitors — TGA / PMDA / NMPA regulatory status
inhibitors regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 37 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 090701 | Phase 3 | Baxalta Innovations | NCT00851721 |
| 090701 | Phase 3 | Takeda | NCT00851721 |
| Aromatase Inhibitors | Phase 3 | United Therapeutics Europe | NCT02338310 |
| BO41423 | Phase 3 | HOFFMANN-LA ROCHE | 2023-506610-52-00 |
| CSET 2021/3373 | Phase 3 | George Institute for | 2023-505380-36-00 |
| CSET 2021/3373 | Phase 3 | George Institute for | 2023-505380-36-01 |
| CSL689 | Phase 3 | CSL Behring | NCT02484638 |
| Concizumab | Phase 3 | Novo Nordisk A/S | NCT04082429 |
| Concizumab | Phase 3 | Novo Nordisk A/S | NCT04083781 |
| FEIBA | Phase 3 | Takeda | NCT02764489 |
| MEDOPP545 | Phase 3 | Stemline Therapeutics (United | 2024-512926-27-00 |
| NN7415-4307 | Phase 3 | NovoThirteen | 2023-506831-13-00 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 20260083736 | GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS FOR USE IN THE TREATMENT OF SUBSTANCE USE DISORDER IN PATIENTS WITH HIGH IMPULSIVITY | US |
| 20260055120 | Bicyclic pyrimidinones as inhibitors of NOX4 | US |
| 20260008777 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | US |
| 20260001878 | SUBSTITUTED PYRROLOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | US |
| 2025304535 | KAT6 Inhibitors | US |
| 12428416 | ERK inhibitors and uses thereof | US |
| 12428379 | Acylsulfonamide KAT6A inhibitors | US |
| 12428415 | Matriptase 2 inhibitors and uses thereof | US |
| 12421273 | Ectonucleotidase inhibitors and methods of use thereof | US |
| 12419890 | Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors | US |
| 12421231 | Azaindole derivatives and their use as ERK kinase inhibitors | US |
| 12421228 | Naphthyridine derivatives as PRC2 inhibitors | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of inhibitors?
inhibitors currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get inhibitors regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to inhibitors?
This spoke lists 37 published programs associated with inhibitors in our pipeline index.